Oct 21, 2026 08:00AM
Oct 15, 2026 08:30AM
Oct 1, 2026 09:15AM
Oct 1, 2026 09:15AM
Oct 1, 2026 08:56AM
Oct 1, 2026 08:56AM
Aug 12, 2026 07:30AM PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Jul 29, 2026 08:30AM
Jul 29, 2026 08:30AM
Jul 22, 2026 06:53AM
Jul 21, 2026 07:30AM
Jul 21, 2026 07:30AM
Jul 21, 2026 07:30AM
Jun 1, 2026 08:32AM PolyPid completes FDA submission for surgical infection prevention drug
Jun 1, 2026 08:30AM
May 13, 2026 07:30AM
Apr 28, 2026 08:30AM
Apr 28, 2026 08:30AM
Mar 31, 2026 08:30AM
Mar 31, 2026 08:30AM
Mar 17, 2026 08:30AM PolyPid receives $4.3 million FDA fee waiver for drug application
Mar 17, 2026 08:30AM
Feb 11, 2026 07:31AM
Feb 11, 2026 07:30AM
Dec 3, 2025 08:32AM
Dec 3, 2025 08:30AM
Nov 25, 2025 08:30AM
Nov 12, 2025 07:30AM PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Nov 6, 2025 08:30AM
Nov 6, 2025 08:30AM
Sep 16, 2025 08:33AM
Sep 16, 2025 08:30AM
Aug 13, 2025 07:30AM
Jun 17, 2025 04:08AM
Jun 16, 2025 07:20PM PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results
Jun 9, 2025 10:13AM
May 14, 2025 07:00AM
Apr 14, 2025 06:54AM
Dec 26, 2024 06:35AM
Dec 23, 2024 07:22PM
Nov 13, 2024 07:00AM
Oct 2, 2024 06:47AM H.C. Wainwright Reiterates Buy Rating on PolyPid Ltd. (PYPD)
Jun 10, 2024 07:00AM
Aug 9, 2023 07:00AM
Jun 29, 2023 08:00AM
Jun 22, 2023 07:00AM
May 22, 2023 09:01AM
May 22, 2023 09:00AM
May 10, 2023 07:00AM PolyPid Provides Corporate Update and Reports First Quarter 2023 Financial Results
Feb 8, 2023 07:00AM

335,363 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All